FDA Proposes Changes to 180-Day Generic Drug Exclusivity Regulations

Summary

The FDA is proposing to update its rules governing the 180-day exclusivity period for generic versions of new drugs, aiming to balance market entry with manufacturer incentives, following recent court decisions that invalidated parts of the current regulations.